Arix Biosciences investee company Aura Biosciences announces positive data from midstage eye cancer trial

Arix Bioscience’s investee company Aura Biosciences announces positive data from mid-stage eye cancer trial

10:46 EDT 30 Oct 2018 | Proactive Investors

The data from a phase Ib/II trial of Aura’s AU-011 eye cancer treatment show the injection doesn’t do too much damage to the surrounding healthy issue in patients’ eyes

More From BioPortfolio on "Arix Bioscience’s investee company Aura Biosciences announces positive data from mid-stage eye cancer trial"